Last reviewed · How we verify
Indacaterol and tiotropium
Indacaterol and tiotropium is a fixed-dose combination of a long-acting beta-2 agonist and a long-acting muscarinic antagonist that work synergistically to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
Indacaterol and tiotropium is a fixed-dose combination of a long-acting beta-2 agonist and a long-acting muscarinic antagonist that work synergistically to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Indacaterol and tiotropium |
|---|---|
| Sponsor | University of Dundee |
| Drug class | LABA/LAMA combination bronchodilator |
| Target | Beta-2 adrenergic receptor and M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Indacaterol is a long-acting beta-2 agonist (LABA) that stimulates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and increased cAMP levels. Tiotropium is a long-acting muscarinic antagonist (LAMA) that blocks M3 muscarinic receptors, preventing acetylcholine-induced bronchoconstriction. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Dry mouth
Key clinical trials
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (PHASE4)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (PHASE3)
- Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indacaterol and tiotropium CI brief — competitive landscape report
- Indacaterol and tiotropium updates RSS · CI watch RSS
- University of Dundee portfolio CI